Le Lézard
Classified in: Health
Subjects: PDT, FVT

Encore Medical Device Repair Introduces Robotic Remanufacturing and Sustainability Program at HSPA


The program is designed to help hospitals reduce the cost of robotic surgery while reducing the environmental footprint of surgeries.

SCOTTSDALE, Ariz., April 16, 2024 /PRNewswire-PRWeb/ -- Encore Medical Device Repair today announced that it will introduce participants to its robotic remanufacturing and sustainability program at the annual conference of the Healthcare Sterile Processing Association (HSPA) in Las Vegas, April 21-23. The initiative is a part of the company's advanced instrument repair program. The annual conference is the sterile processing profession's leading in-person educational and networking event.

The cost of robotic instruments is simply too high, and we want to work with sterile processing and hospital executives to bring these costs down.

The instrument repair industry is challenged with long repair times, low-quality repairs, high rates of instrument unrepairability, and lack of cost transparency. Encore combines the most qualified technologists in the industry with control of the parts supply chain and a customer-focused repair offering to deliver enhanced reliability and unique customer value. The company's commitment to elevating the industry from instrument repair to asset stewardship penetrates its operations from instrument repair to staff education. Ultimately, the quality of medical instruments is directly related to the quality of patient care.

"Sterile processing professionals play a key role in protecting the hospital's operational efficiency and patient safety. I am looking forward to discussing our new robotic sustainability program with the highly competent and hard-working professionals at the conference," says Encore President and COO Tom Milano. "The cost of robotic instruments is simply too high, and we want to work with sterile processing and hospital executives to bring these costs down."

The robotic remanufacturing and sustainability program allows hospitals to either purchase remanufactured robotic instruments or collect certain robotic accessories to obtain credit for instrument repair work.

Encore was formed in 2023 through the merger of several medical instrument repair and parts companies. The company offers a full suite of instrument repair services. Through its collaboration with Restore Robotics, Encore is the only company that can sell FDA cleared remanufactured robotic instruments.

About Encore Medical Device Repair
Encore Medical Device Repair was founded in 2022 on the vision that device and instrument reuse should play a key role in responsible healthcare. To achieve this, the founders knew they had to raise the level of quality, sophistication, transparency, and service in the industry. A focus on the highest-price, highest-utilization instrument categories allows Encore to employ the most qualified technicians and deliver unparalleled service while containing costs.

Media Contact

Lori Luechtefeld, WIT Strategy for Encore Medical Device Repair, 310-210-4757, [email protected], https://encoremdr.com

SOURCE Encore Medical Device Repair


These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: